SGX Market Updates

SGX’s Most Traded Healthcare Stocks Gain 6% Since March


PUBLISHED ON |

21 June 2021

  • The Healthcare Sector led the global stock market in the 2Q21 to 18 June, as healthcare services and equipment continued to outpace biotechnology and pharmaceutical stocks. The top quartile of global Healthcare stocks by market value have generated a median 7% gain in the 2Q21 to 18 June.

  • Singapore’s iEdge SG All Healthcare Index has closely followed the global trend, generating a 5% total return in the 2Q21 to 18 June. The 10 most traded stocks of the Index have also averaged a 6% total return in the 2Q21 to 18 June, bringing their average 12M return to 53%.

  • Among the Index constituents, Medtecs International was recipient to the highest net institutional and net proprietary inflow (S$8.2M) proportionate to market capitalisation (S$505M) in the 2Q21 to 18 June. Through its Amazon US shop, the Group increased its 1Q21 daily sales volume by more than tenfold from 4Q20.

  • Index constituents that generated double-digit total returns in 2Q21 to 18 June included First REIT (23%), Riverstone (15%) and Q&M Dental Group (14%) which are among the 10 most traded stocks of the Index, and outside the 10 most traded stocks, Tianjin Zhongxin Pharmaceutical (14%), iX Biopharma (14%), HC Surgical Specialists (14%) and Cordlife Group (13%).




Over the course of 2Q21, the return to more normalised economic conditions emerged as the key motif of global markets, earnings reports, institutional flows and industry reports. Apart from global progress in vaccine rollouts, normalisation was underlined by significant year-on-year rebounds in key economic data across the globe, in addition to ongoing sequential recoveries. During the quarter, the Straits Times Index (“STI”) consolidated on its strong 4Q20 and 1Q20 gains, generating a marginal 0.5% total return in the 2Q21 quarter to 18 June. The strongest global sector of the 2Q21 to 18 June, Healthcare does not maintain any weightage in the STI. This was a contrast to 1Q21, when the under significant STI benefitted from Banks ranking the strongest sector across the globe on resilient investment and higher treasury yields.

According to the Deloitte Insights 2021 global healthcare outlook, consumers are driving and accelerating the pace of change in health care with COVID-19 challenging consumer’s sense of well-being and accelerated their desire and determination to become more active, engaged, and empowered in managing their health.

Singapore’s iEdge SG All Healthcare Index generated a 5.3% total return in the 2Q21 to 18 June, with its 10 most traded stocks averaging a 6.2% total return over the 11 weeks. As illustrated below, the iEdge SG All Healthcare Index has also been more aligned with the median performance of the top quartile of global healthcare stocks, this quarter, in comparison to the preceding three quarters.



Performance Of SGX Healthcare Stocks



Global healthcare stocks generally trade at higher valuations to the broader market. The past 12 months have seen a modest level of convergence in the price-to-book ratios of Singapore-listed healthcare stocks and the global leaders of the Healthcare Sector. Since June 2020, the top quartile of global healthcare stocks have extended their premium to book value by 6%, whilst the constituents of Singapore’s iEdge SG All Healthcare Index have seen their median premium to book value extend by 9%.

The 10 most traded stocks of the iEdge SG All Healthcare Index are tabled below and sorted by highest average daily turnover in the 2021 year to 18 June. The 10 stocks include three of the strongest constituents of the Index in 2Q21 to 18 June.


10 Most Traded Stocks of
the iEdge SG All Healthcare Index
in 2021 YTD
SGX
Code
Market
Cap
S$m
YTD
Average Daily
Turnover
S$M
QTD
Net Institutional
& Net Proprietary Flow
S$M
QTD
Total Return
%
YTD
Total Return
%
12-Month
Total Return
%
SGX Board
Medtecs International 546 505 8.2 8.1 5.3 -2.0 209.0 CATALIST
Top Glove BVA 12,247 7.7 -17.4 0.7 -19.7 -0.7 MAINBOARD
Riverstone AP4 2,001 5.5 10.8 14.7 27.1 22.6 MAINBOARD
Thomson Medical Group A50 2,380 5.3 -4.0 -19.6 80.0 55.2 MAINBOARD
UG Healthcare 8K7 373 3.8 -10.8 8.0 3.6 126.4 CATALIST
Haw Par H02 2,943 3.1 17.2 2.3 25.7 31.8 MAINBOARD
Q&M Dental Group QC7 563 2.6 -4.0 14.3 62.2 70.9 MAINBOARD
ParkwayLife REIT C2PU 2,656 2.6 -0.6 8.5 15.4 30.7 MAINBOARD
Raffles Medical Group BSL 2,166 2.4 4.5 5.5 18.7 36.7 MAINBOARD
First REIT AW9U 442 1.4 1.0 22.6 34.5 -56.0 MAINBOARD
Average 6.2 24.5 52.7

Source: SGX, Refinitiv, Bloomberg (Data as of 18 June 2021)



Among the iEdge SG All Healthcare Index constituents, Medtecs International was recipient to the most trading activity in the 2021 year to 18 June. Medtecs International was also recipient to the highest net institutional and net proprietary inflow (S$8.2M) proportionate to market capitalisation (S$505M) among the constituents, in the 2Q21 to 18 June. As reported on 6 May, Medtecs International has started site selection for the construction of a personal protective equipment (“PPE”) manufacturing facility to further strengthen the Group's position as a leading PPE stockpiling provider and Asia’s first multi-national group procurement platform with one-stop shop capabilities. In addition, Medtecs International has continued to expand its retail business, including through its Amazon US shop, which has increased its 1Q21 daily sales volume by more than 10 times from 4Q20.

Other stocks of the Singapore’s iEdge SG All Healthcare Index that generated double digit gains in the 2Q21 to 18 June beyond the 10 tabled above included Tianjin Zhongxin Pharmceutical, iX Biopharma, HC Surgical Specialists and Cordlife Group. These 4 stocks generated similar gains in the 2Q21 to 18 June, averaging a 13.9% total return. Note iX Biopharma and HC Surgical Specialists are both listed on Catalist.

SGX Mainboard listed Thomson Medical Group, and Catalist-listed stocks AOXIN Q & M Dental Group, Singapore Medical Group, QT Vascular and Singapore Paincare Holdings were the least performing stocks of the Index in the 2Q21 to 18 June, averaging 15.7% decline, trimming their average total return for the past 12 months to 28.0%.

The combined market capitalisation of the constituents of the iEdge SG All Healthcare Index is S$48 billion which represents 5% of the total market capitalisation of all stocks listed on Singapore Exchange at S$905 billion. The iEdge SG All Healthcare Index combined market capitalisation has grown by 37% since the end of 2019. Business activities within the healthcare sector include, but are not limited to, healthcare providers, manufacturing and distribution of medical equipment and supplies, pharmaceutical companies, biotechnology companies or healthcare asset owners.







This article is provided by SGX My Gateway.



SGX My Gateway

SGX's investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.

This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the SGX Group Companies) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.












Stock / REIT Search

Advertisement

Advertisement